Telix Doses First Patient in Phase 3 BiPASS Trial: PSMA-PET Imaging for Prostate Cancer Diagnosis
1. Telix doses first patient in Phase 3 trial for prostate cancer. 2. Combination of MRI and PSMA-PET aims to optimize biopsy processes. 3. Potential market for imaging agents could expand by 800,000 scans. 4. Study leverages previous successful trials to improve diagnostic accuracy. 5. Innovative techniques may transform prostate cancer diagnosis and treatment.